CRGX — CARGO Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $198.95m
- -$140.76m
Annual income statement for CARGO Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 5.98 | 34.8 | 99 | 187 |
| Operating Profit | -5.98 | -34.8 | -99 | -187 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -5.85 | -41 | -98.1 | -168 |
| Net Income After Taxes | -5.85 | -41 | -98.1 | -168 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -5.85 | -41 | -98.1 | -168 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -5.85 | -41 | -98.1 | -168 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.151 | -1.06 | -2.33 | -3.72 |
| Dividends per Share |